Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different doses of botulinum toxin A for treatment-resistant rhinitis
IRCT20251101067850N1Phase 2Completed
- Sponsor
- Baqiyatallah University of Medical Sciences
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abobotulinumtoxinA and botulinum toxin type A in rhinitis (3 arms), sponsored by Baqiyatallah University of Medical Sciences. Primary endpoints: Minimum effective dose with greatest effect and duration for symptom control and Total Nasal Symptom Score. Started Dec 2025; status: completed.
02
Drugs
abobotulinumtoxinAbotulinum toxin type A
03
Conditions
rhinitis
Beyond the preview
Go deeper on IRCT20251101067850N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251101067850N1.